Therefore, we hypothesize that targeting DHODH activity in MCL, using (R)‐HZ05, as a single‐agent and as a combinatory agent, represents a promising and yet unexplored strategy in MCL. The gene discussed is DHODH; the disease is mantle cell lymphoma.